Available treatment options for the management of Lambert-Eaton myasthenic syndrome. (Q34542581)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16805718%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

review article

1 reference

title

Available treatment options for the management of Lambert-Eaton myasthenic syndrome (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16805718%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16805718%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16805718%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

Paul W Wirtz

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16805718%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

Luuk N A Willems

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16805718%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

Joop van Gerven

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16805718%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

language of work or name

English

0 references

publication date

1 July 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16805718%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Pharmacotherapy

26 December 2019

number of pages

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16805718%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16805718%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16805718%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

page(s)

1323-1336

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16805718%20AND%20SRC:MED&resulttype=core&format=json

Bronchial neoplasm with myasthenia; prolonged apnoea after administration of succinylcholine

26 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1323

Carcinomatous neuropathy and myopathy a clinical and pathological study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1323

Peripheral neuropathy and myopathy associated with bronchogenic carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1323

The Lambert-Eaton myasthenic syndrome. A review of 50 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1323

The epidemiology of myasthenia gravis, Lambert-Eaton myasthenic syndrome and their associated tumours in the northern part of the province of South Holland.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1323

Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1323

A susceptibility region for myasthenia gravis extending into the HLA-class I sector telomeric to HLA-C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1323

Difference in distribution of muscle weakness between myasthenia gravis and the Lambert-Eaton myasthenic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1323

Differences in clinical features between the Lambert-Eaton myasthenic syndrome with and without cancer: an analysis of 227 published cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1323

Plasmapheresis and immunosuppressive drug therapy in the Eaton-Lambert syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1323

Evaluation of 4-aminopyridine and 3,4-diaminopyridine penetrability into cerebrospinal fluid in anesthetized rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1323

The effects of 4-aminopyridine in multiple sclerosis patients: results of a randomized, placebo-controlled, double-blind, concentration-controlled, crossover trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1323

TREATMENT OF MYASTHENIA GRAVIS WITH PHYSOSTIGMINE

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1323

Intravenous immunoglobulin in autoimmune neuromuscular diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1323

Eaton-lambert myasthenic syndrome: Long-term treatment of three patients with prednisone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1323

Lambert-Eaton myasthenic syndrome (LEMS). Clinical and electrodiagnostic features and response to therapy in 59 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1323

Lambert-eaton myasthenic syndrome: diagnosis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1323

A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1323

Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1323

Second-line chemotherapy in recurrent small cell lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1323

Management of small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1323

Prognostic factors for patients with small cell lung carcinoma: analysis of a series of 763 patients included in 4 consecutive prospective trials with a minimum follow-up of 5 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1323

Favourable prognosis in Lambert-Eaton myasthenic syndrome and small-cell lung carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1323

Clinical practice. Lung cancer screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1323

Lambert-Eaton myasthenic syndrome has a more progressive course in patients with lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1323

Treatment of autoimmune myasthenia gravis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1323

21 January 2018

Letters to the editor

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1323

10.1517/14656566.7.10.1323

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16805718%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16805718%20AND%20SRC:MED&resulttype=core&format=json